NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 12:05Irma Bagdoniene: The Silent Progression of Coronary Artery Disease
-
Jul 27, 2026, 12:03A Novel Strategy to Rebalance Immunity in ITP – JTH
-
Jul 27, 2026, 11:45Ericka Robinson: Welcoming Vishakha K. Kumar to ISTH
-
Jul 27, 2026, 11:26ISTH Appoints a New CEO
-
Jul 27, 2026, 11:21Peter Bou Dib: How Lipocalin-2 Shapes the Immune Response After Stroke
-
Jul 27, 2026, 11:10Tareq Abadl: CSF Culture – Understanding Cerebrospinal Fluid Testing
-
Jul 27, 2026, 11:05Abdul Mannan: CTEPH – The Treatable Cause of Post-PE Breathlessness
-
Jul 27, 2026, 10:33Akshay Kumar Chopra: Exploring Complex Immunohematology Cases at ISBT Academic Day 2026
-
Jul 27, 2026, 09:54Robert Hamilton: A New ”Game-Changing” Approach for Identifying PFOs in Stroke